Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Phase III NCT05895786

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] — Recruiting • Phase III •…

📅 30 Mar 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase III
NCT ID
NCT05895786
Start
2023-05-20
Completion
2027-07-28
ClinicaliQ Trial Snapshot
  • A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] — Recruiting • Phase III • Dermatology • NCT05895786.
  • Review the linked registry entry for study design, population, endpoints, and operational status.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of the study is to understand how the study medicine PF-06823859 (dazukibart) works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the muscles that are important for movement and may also cause skin rash in people with DM. This study is seeking participants who: * Are 18 years of age or older or minimum legal adult age as defined per local regulation, whichever is greater * Have active DM or active PM. * Are receiving a stable dose of 1 corticosteroid…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)
Dermatology · 08 Apr 2026
This NICE publication is marked as a terminated appraisal, so it functions as a status notice rather than an active treatment recommendation…
View guideline →
Clinical Brief
Topical steroids: introduction of new labelling and a reminder of the possibility of severe side effects, including Topical Steroid Withdrawal Reactions
Dermatology · MHRA · 29 May 2024
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have…
View brief →
Guideline
Hidradenitis Suppurativa: Assessment and Management (NICE NG73)
Dermatology · 27 Mar 2026
Diagnose hidradenitis suppurativa clinically based on recurrent painful nodules, abscesses, sinus tracts, and scars localised to intertriginous areas (axillae, groin, inframammary folds),…
View guideline →
Guideline
Atopic Eczema in Under 12s: Diagnosis and Management (NICE NG190)
Dermatology · 27 Mar 2026
Diagnose atopic eczema clinically based on itching, typical morphology and distribution, onset before age 2 years, and history of dry skin or…
View guideline →
Guideline
Non-Melanoma Skin Cancer: Diagnosis and Management (NICE NG12)
Dermatology · 27 Mar 2026
Refer suspected BCC or SCC to specialist dermatology using 2-week wait pathway if diagnosis is clear; use urgent referral for lesions >4…
View guideline →
Clinical Brief
Tens of thousands with vitiligo to be offered “life-changing” new cream on NHS to restore skin colour
Dermatology · NHS England · 24 Feb 2026
Tens of thousands of people living with vitiligo affecting their face are to be offered the first approved medicine on the NHS…
View brief →